Potential CV effect | Drug class | Drug | Total population | Patients who underwent extended monitoring | P-value* |
---|---|---|---|---|---|
Bradycardia | Antihypertensive | Beta-blockers | 6 (0.7) | 0 | NS |
Anti-epilepsy, anti-migraine | Topiramate | 8 (0.9) | 2 (0.6) | 0.03 | |
Prolong QT interval | Anti-fatigue | Amantadine | 18 (2.0) | 1 (0.3) | NS |
Modafinil | 4 (0.4) | 0 | NS | ||
4-Aminopiridine | 5 (0.5) | 2 (0.6) | 0.01 | ||
Antidepressant | Tricyclicsa | 10 (1.1) | 0 | NS | |
SSRIsb | 58 (6.4) | 1 (0.3) | NS | ||
Escitalopram | 26 (2.9) | 1 (0.3) | NS | ||
SNRIsc | 35 (3.9) | 2 (0.6) | NS | ||
Duloxetine | 21 (2.3) | 2 (0.6) | NS | ||
Trazodone | 1 (0.1) | 1 (0.3) | 0.03 | ||
Bupropion | 2 (0.2) | 0 | NS | ||
Mirtazapine | 3 (0.3) | 0 | NS | ||
Anti-psychotics | 7 (0.8) | 0 | NS | ||
Muscle relaxants | Tizanidine | 3 (0.3) | 0 | NS | |
Antimuscarinic drugs | Tolterodine | 2 (0.2) | 0 | NS | |
Solifenacin | 5 (0.5) | 0 | NS | ||
Antibiotics | Macrolides | 1 (0.1) | 0 | NS | |
Otherd | Benzodiazepines | 39 (4.3) | 2 (0.6) | NS | |
ACE-inhibitors | 14 (1.5) | 1 (0.3) | NS | ||
Gabapentin | 24 (2.6) | 2 (0.6) | NS | ||
Levotiroxine | 40 (4.4) | 2 (0.6) | NS | ||
Tamsulosin | 12 (1.3) | 1 (0.3) | NS | ||
Baclofen | 39 (4.3) | 1 (0.3) | NS |